Trial Profile
Global Lomitapide Pregnancy Exposure Registry
Status:
Discontinued
Phase of Trial:
Phase IV
Latest Information Update: 19 Dec 2022
Price :
$35
*
At a glance
- Drugs Lomitapide (Primary)
- Indications Hyperlipoproteinaemia type IIa
- Focus Adverse reactions
- Sponsors Aegerion Pharmaceuticals; Amryt Pharma
- 14 Dec 2022 Status changed from recruiting to discontinued.
- 13 Jan 2016 Status changed from not yet recruiting to recruiting as reported by ClinicalTrials.gov.
- 27 Mar 2015 New trial record